Umberto Vitolo, MD, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy, discusses treatment strategies in diffuse large B-cell lymphoma (DLBCL), highlighting the unmet need in this area. Prof. Vitolo first explains how treatment approaches have not advanced over the years, and then highlights the potential value of polatuzumab vedotin in this space. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
The need for new treatment strategies for patients with DLBCL
Теги
Speaker: Umberto VitoloInstitution: Candiolo Cancer InstituteEvent: SOHO 2022Format: InterviewSubject: LymphomaSubject: Non-Hodgkin LymphomaSubject: Diffuse large B-cell lymphomaField: TreatmentField: Immuno-OncologyField: Trial UpdatesField: PerspectivesMedicines: AntibodiesMedicines: RituximabMedicines: Polatuzumab VedotinMedicines: LenalidomideMedicines: ObinutuzumabMedicines: R-CHOPTrial: POLARIXNCT03274492
